"Working with the National Fibromyalgia Association will provide Swiss Medica with a unique opportunity to introduce our patented, safe, effective and completely natural pain relief technology to people with fibromyalgia. With O24 Fibromyalgia™, we are making an unprecedented and on-going commitment to support the much-needed services that the NFA provides to fibromyalgia sufferers." -Grant Johnson, President, Swiss Medica

"We are thrilled that Swiss Medica has developed and clinically tested O24 Fibromyalgia™ specifically for people with fibromyalgia. Their commitment to the patient community is impressive, and with their support, the National Fibromyalgia Association will be able to take its patient service programs and future research to a new level, reaching even more people with fibromyalgia." -Lynne Matallana, Executive Director, National Fibromyalgia Association

O24 Fibromyalgia™ Receives First-Ever National Fibromyalgia Association Official Seal of Approval

Swiss Medica Inc. announced the launch of its keenly anticipated O24 Fibromyalgia™ pain reliever during a joint press announcement with the National Fibromyalgia Association at the June National Association of Chain Drug Stores Marketplace conference in New Orleans.

Patented, clinically tested, and all-natural, the O24 Fibromyalgia™ is the first product of its kind developed specifically to address the chronic pain associated with fibromyalgia, and to be sold over-the-counter in retail pharmacies. The palm-sized O24™ towelettes, which contain eucalyptus, aloe vera, peppermint, rosemary, lemon and orange oils, can be applied to painful areas of the body to decrease pain.

As part of the launch, Swiss Medica also announced a strategic partnership with the NFA. Executive Director Lynne Matallana spoke about the challenge of living with fibromyalgia and explained why O24 Fibromyalgia™ pain reliever has become the first product to carry the NFA’s new Official Seal of Approval on its packaging.

"Working with the National Fibromyalgia Association will provide Swiss Medica with a unique opportunity to introduce our patented, safe, effective and completely natural pain relief technology to people with fibromyalgia," said Grant Johnson, President of Swiss Medica Inc. "It’s also the start of an on-going commitment to support the much-needed services that the NFA provides to fibromyalgia sufferers."

As part of this strategic partnership, the non-profit NFA will receive a percentage of the proceeds from the sale of O24 Fibromyalgia™. This revenue will directly benefit people with fibromyalgia by supporting the programs and services of the NFA.

"The fibromyalgia community is desperate for safe, effective treatment options to help reduce fibromyalgia symptoms, including long-term widespread muscle pain," said Matallana.

"Even though there are up to 11 million Americans suffering with fibromyalgia, there have been only a few products developed and clinically tested to evaluate their effectiveness specifically for fibromyalgia pain. We are pleased that Swiss Medica has not only developed such a product, but is now committed to helping support patient service programs and future research implemented by the NFA to directly benefit the FM community. The NFA’s partnership with Swiss Medica will be an incalculable benefit to our 400,000 members."

Johnson also discussed the previously announced results of a recently completed randomized double blind clinical trial that compared the O24 Fibromyalgia™ pain reliever against a placebo on patients suffering fibromyalgia. This double blind clinical trial was conducted earlier this year at the University of Toronto’s Sunnybrook & Women’s Health Sciences Centre.

The pilot study, conducted over a four-to-six week period, compared the O24 Fibromyalgia™ pain reliever against a placebo in patients suffering with fibromyalgia. 68 (51%) used a placebo. The other 65 (49%) used the O24 Fibromyalgia™ product.

For participants who used O24 Fibromyalgia™, more than 90 percent of the patients reported mild to markedly better improvement. More than half reported moderately better or markedly better results using O24 Fibromyalgia™ instead of the placebo.

National Fibromyalgia Association
2200 N. Glassell St., Suite A, Orange, Ca 92865
Phone: 714-921-0150 Fax: 714-921-6920

The information contained in this web site is not a substitute for professional medical advice. Please always consult with your physician on all matters related to your health and medical treatment.